Camac Fund holds 6.8% Cryo-Cell (CCEL) stake and may engage board

Rhea-AI Filing Summary

Camac Fund and related entities filed an amended Schedule 13D reporting a significant stake in Cryo-Cell International. Camac Fund beneficially owns 551,081 shares of Cryo-Cell common stock, representing approximately 6.8% of the 8,055,150 shares outstanding as of April 14, 2026. The fund acquired these shares for an aggregate purchase price of about $1,807,998 using working capital, which may include margin loans.

The reporting group, including Camac Partners, Camac Capital and manager Eric Shahinian, states it bought the shares because it viewed them as undervalued and an attractive investment. They indicate they may increase or decrease their position and may engage with Cryo-Cell’s management and board on topics such as board composition, corporate governance, spending levels, asset monetization and returning capital to shareholders.

Key Figures

Beneficial ownership: 551,081 shares Ownership percentage: 6.8% Shares outstanding: 8,055,150 shares +3 more

6 metrics

Beneficial ownership 551,081 shares Camac Fund beneficially owned shares as reported in Schedule 13D/A

Ownership percentage 6.8% Percent of Cryo-Cell common stock class represented by 551,081 shares

Shares outstanding 8,055,150 shares Cryo-Cell common stock outstanding as of April 14, 2026 from Form 10-Q

Aggregate purchase price $1,807,998 Approximate total cost, including commissions, of 551,081 shares

Shared voting power 551,081 shares Shares over which each reporting person has shared voting power

Shared dispositive power 551,081 shares Shares over which each reporting person has shared dispositive power

Key Terms

beneficially owned, working capital, margin loans, dispositive power, +2 more

6 terms

beneficially owned financial

"The aggregate purchase price of 551,081 Shares beneficially owned by Camac Fund is approximately $1,807,998"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

working capital financial

"The Shares purchased by Camac Fund were purchased with working capital (which may, at any given time, include margin loans...)"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

margin loans financial

"working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business)"

Margin loans are loans from a brokerage that let an investor borrow money using their existing stocks, bonds or cash as collateral to buy more securities. They matter because borrowing magnifies both gains and losses—like using a lever to move a heavier load—so small market moves can have outsized effects on your returns; investors also pay interest and risk a margin call, where the broker may force sales if collateral falls below required levels.

dispositive power financial

"Shared Dispositive Power 551,081.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13D regulatory

"If the filing person has previously filed a statement on Schedule 13G to report the acquisition..."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Joint Filing Agreement regulatory

"Each of the Reporting Persons, is party to that certain Joint Filing Agreement, as further described in Item 6"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/07/2026 - 09:02 AM Accepted by SEC EDGAR 07/07/2026 - 09:01 AM Learn about SEC filing dates

FAQ

How big is Camac Fund’s stake in Cryo-Cell International (CCEL)?

Camac Fund reports beneficial ownership of 551,081 Cryo-Cell shares, representing about 6.8% of the company. This percentage is based on 8,055,150 shares of common stock outstanding as of April 14, 2026, from Cryo-Cell’s Form 10-Q.

What did Camac Fund pay for its Cryo-Cell (CCEL) position?

Camac Fund states it paid an aggregate purchase price of approximately $1,807,998 for its 551,081 Cryo-Cell shares. The filing notes that the purchases were funded with working capital, which may at times include margin loans from brokerage firms.

Why did Camac Fund invest in Cryo-Cell International (CCEL)?

The reporting group says it bought Cryo-Cell shares because it believed they were undervalued and an attractive investment opportunity when purchased. This reflects their investment view at the time, not a guarantee of future performance or a stated price target.

How might Camac Fund’s 6.8% stake affect Cryo-Cell (CCEL)?

The group may increase or decrease its position and considers various open-market or private transactions. It also signals potential engagement with management and the board on issues like governance, spending, monetizing company assets and returning capital to shareholders.

Who are the reporting persons in the Cryo-Cell (CCEL) Schedule 13D/A?

The filing names Camac Fund, LP, Camac Partners, LLC, Camac Capital, LLC, and Eric Shahinian as reporting persons. They report shared voting and dispositive power over the same 551,081 shares through their investment and management roles.

What level of control does Camac Fund report over Cryo-Cell (CCEL) shares?

Each reporting person shows 0 shares with sole voting or dispositive power and 551,081 shares with shared voting and dispositive power. This means decisions to vote or sell these shares are controlled collectively through their roles with Camac Fund.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

CRYO CELL INTERNATIONAL INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

228895108

(CUSIP Number)

ERIC SHAHINIAN
CAMAC PARTNERS, LLC, 1601-1 N. MAIN STEET #3159, SMB#92283
JACKSONVILLE, FL, 32206
914-629-8496

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 228895108

1

Name of reporting person

Camac Partners, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 551,081.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 551,081.00

11

Aggregate amount beneficially owned by each reporting person

551,081.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 228895108

1

Name of reporting person

Camac Capital, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 551,081.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 551,081.00

11

Aggregate amount beneficially owned by each reporting person

551,081.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 228895108

1

Name of reporting person

Camac Fund, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 551,081.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 551,081.00

11

Aggregate amount beneficially owned by each reporting person

551,081.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 228895108

1

Name of reporting person

Eric Shahinian

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 551,081.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 551,081.00

11

Aggregate amount beneficially owned by each reporting person

551,081.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: CRYO CELL INTERNATIONAL INC
(c)	Address of Issuer's Principal Executive Offices: 700 BROOKER CREEK BLVD, Suite 1800, Oldsmar, FLORIDA , 34677.
Item 2.	Identity and Background
(a)	(a) This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on March 25, 2026 by: (i) Camac Partners, LLC, a Delaware limited liability company ("Camac Partners") (ii) Camac Capital, LLC, a Delaware limited liability company ("Camac Capital") (iii) Camac Fund, LP, a Delaware partnership ("Camac Fund"); and (iv) Eric Shahinian, an individual, residing in FL ("Eric Shahinian"), who serves as the manager of Camac Capital, LLC. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons". Each of the Reporting Persons, is party to that certain Joint Filing Agreement, as further described in Item 6 and filed as an exhibit to this Schedule 13D. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.
(b)	The address of the principal office of each of the Reporting Persons is 1601-1 N. Main Street #3159, SMB#92283, Jacksonville, FL 32206.
(c)	The principal business of Camac Fund is investing in securities. Camac Partners is the investment manager of Camac Fund. Camac Capital is the general partner of Camac Fund. The principal occupation of Eric Shahinian is serving as the manager of Camac Capital, the general partner of Camac Fund.
(d)	During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Camac Partners, Camac Capital, and Camac Fund are organized under the laws of Delaware. Eric Shahinian is a United States Citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	The Shares purchased by Camac Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of 551,081 Shares beneficially owned by Camac Fund is approximately $1,807,998 including brokerage commissions.
Item 4.	Purpose of Transaction
	The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor to (i) increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) enter into transactions that increase or hedge their economic exposure to the securities of the Issuer without affecting their beneficial ownership of the Shares. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed herein. The Reporting Persons intend to review their investments in the Issuer on a periodic basis and may from time to time engage in communications and discussions with management and the Board of Directors of the Issuer (the "Board"), other stockholders of the Issuer and third parties concerning, among other things, Board composition and corporate governance, levels of expenditures, monetization of all of the company's assets, and return of capital to shareholders. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.
Item 5.	Interest in Securities of the Issuer
(a)	The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 8,055,150 shares of Common Stock outstanding, which is the total number of shares of Common Stock reported outstanding as of April 14, 2026, on the Issuer's Form 10-Q, filed with the Securities and Exchange Commission on April 14, 2026. As of the date of this filing, Camac Fund beneficially owned 551,081 shares of Common Stock. Percentage: Approximately 6.8%
(b)	By virtue of their respective positions with Camac Fund, each of Camac Partners, Camac Capital, and Eric Shahinian may be deemed to have shared power to vote and dispose of the Shares reported owned by Camac Fund.
(c)	Schedule A annexed hereto lists all transactions in securities of the Issuer by the Reporting Persons during the past 60 days.
(d)	No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Exhibit 99.1 Joint Filing Agreement.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Camac Partners, LLC

Signature:	/s/ Eric Shahinian
Name/Title:	Eric Shahinian/Managing Member of the GP
Date:	07/07/2026

Camac Capital, LLC

Signature:	/s/ Eric Shahinian
Name/Title:	Eric Shahinian/Managing Member
Date:	07/07/2026

Camac Fund, LP

Signature:	/s/ Eric Shahinian
Name/Title:	Eric Shahinian/Managing Member of the GP
Date:	07/07/2026

Eric Shahinian

Signature:	/s/ Eric Shahinian
Name/Title:	Eric Shahinian
Date:	07/07/2026